Ayala Pharmaceuticals Inc ADXS:OTCQX

*Data is delayed | Exchange | USD
Last | 05/16/24 EDT
0.22quote price arrow up+0.03 (+15.7895%)
Volume
8,699
52 week range
0.14 - 1.95
Loading...
  • Open0.20
  • Day High0.22
  • Day Low0.20
  • Prev Close0.22
  • 52 Week High1.95
  • 52 Week High Date07/24/23
  • 52 Week Low0.14
  • 52 Week Low Date05/15/24

Key Stats

  • Market Cap9.379M
  • Shares Out42.63M
  • 10 Day Average Volume28,582.7
  • Dividend-
  • Dividend Yield-
  • Beta1.46
  • YTD % Change-67.02

KEY STATS

  • Open0.20
  • Day High0.22
  • Day Low0.20
  • Prev Close0.22
  • 52 Week High1.95
  • 52 Week High Date07/24/23
  • 52 Week Low0.14
  • 52 Week Low Date05/15/24
  • Market Cap9.379M
  • Shares Out42.63M
  • 10 Day Average Volume28,582.7
  • Dividend-
  • Dividend Yield-
  • Beta1.46
  • YTD % Change-67.02

RATIOS/PROFITABILITY

  • EPS (TTM)-7.46
  • P/E (TTM)-0.03
  • Fwd P/E (NTM)-0.30
  • EBITDA (TTM)-35.897M
  • ROE (TTM)-49.22%
  • Revenue (TTM)13,000.00
  • Gross Margin (TTM)-
  • Net Margin (TTM)-369,784.59%
  • Debt To Equity (MRQ)-33.34%

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Ayala Pharmaceuticals Inc

 

Content From Our Affiliates

There is no recent news for this security.

Profile

MORE
Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company primarily focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations. The Company's lead candidate is aspacytarabine (BST-236), a novel anti-metabolite for first line treatment in unfit acute myeloid leukemia (AML). Aspacytarabine (BST-236) is composed of cytarabine covalently bound to...
David Sidransky
Independent Chairman of the Board
Kenneth Berlin J.D.
President, Chief Executive Officer, Director
Roy Golan CPA
Chief Financial Officer
Address
9 DEER PARK DRIVE, SUITE K-1
Monmouth Junction, NJ
08852
United States

Top Peers

SYMBOLLASTCHG%CHG
EVAX
Evaxion Biotech A/S
3.83-0.04-1.03%
GLTO
Galecto Inc
0.63-0.0022-0.348%
AIM
AIM ImmunoTech Inc
0.39-0.0096-2.4024%
NRBO
NeuroBo Pharmaceuticals Inc
4.60+0.36+8.49%
COCP
Cocrystal Pharma Inc
1.97-0.13-6.43%